[go: up one dir, main page]

HK1221216A1 - 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用於治疗癌症 - Google Patents

2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用於治疗癌症 Download PDF

Info

Publication number
HK1221216A1
HK1221216A1 HK16109232.1A HK16109232A HK1221216A1 HK 1221216 A1 HK1221216 A1 HK 1221216A1 HK 16109232 A HK16109232 A HK 16109232A HK 1221216 A1 HK1221216 A1 HK 1221216A1
Authority
HK
Hong Kong
Prior art keywords
methyl
amino
mmol
compound
mixture
Prior art date
Application number
HK16109232.1A
Other languages
English (en)
Other versions
HK1221216B (zh
Inventor
Sam Butterworth
Maurice Raymond Verschoyle Finlay
Richard Andrew Ward
Vasantha Krishna Kadambar
Chandrasekhara Reddy Chintakuntla
Andiappan Murugan
Claudio Edmundo Chuaqui
Heather Marie Redfearn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1221216(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1221216A1 publication Critical patent/HK1221216A1/zh
Publication of HK1221216B publication Critical patent/HK1221216B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Liquid Crystal Substances (AREA)
HK16109232.1A 2011-07-27 2016-08-03 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用於治疗癌症 HK1221216B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161512061P 2011-07-27 2011-07-27
US201161512061P 2011-07-27
US201261591363P 2012-01-27 2012-01-27
US201261591363P 2012-01-27

Publications (2)

Publication Number Publication Date
HK1221216A1 true HK1221216A1 (zh) 2017-05-26
HK1221216B HK1221216B (zh) 2018-08-10

Family

ID=

Also Published As

Publication number Publication date
BR122014026150A2 (pt) 2019-05-28
PH12013502312A1 (en) 2016-07-13
CA2843109A1 (en) 2013-01-31
TW201319057A (zh) 2013-05-16
ECSP13013033A (es) 2014-01-31
IL242284A0 (en) 2015-11-30
BR122014026094A2 (pt) 2019-08-20
EP3686194A1 (en) 2020-07-29
ME03785B (me) 2021-04-20
HUE049060T2 (hu) 2020-08-28
HK1192549A1 (zh) 2014-08-22
IL242279A (en) 2016-07-31
RS60190B1 (sr) 2020-06-30
SG194783A1 (en) 2013-12-30
IL242286A (en) 2016-07-31
PH12015501326B1 (en) 2015-09-14
NZ617393A (en) 2014-11-28
CR20130629A (es) 2014-03-12
SG10201910984XA (en) 2020-01-30
PT3686194T (pt) 2021-11-11
IL242284A (en) 2016-07-31
CN105198862B (zh) 2018-01-23
ES2914854T3 (es) 2022-06-17
AR087336A1 (es) 2014-03-19
IL229199A0 (en) 2014-01-30
SG10201910986QA (en) 2020-01-30
ES2791308T3 (es) 2020-11-03
IL242285A (en) 2016-07-31
JP2014139226A (ja) 2014-07-31
LT3686194T (lt) 2021-11-25
EP2736895A1 (en) 2014-06-04
KR101691268B1 (ko) 2016-12-29
CN105175396B (zh) 2018-01-16
US10858336B2 (en) 2020-12-08
ME02382B (me) 2016-06-20
CY1125405T1 (el) 2023-03-24
DK3333161T3 (da) 2020-05-18
IL229199A (en) 2015-11-30
IL242278A0 (en) 2015-11-30
DOP2013000263A (es) 2014-01-31
CN104109151A (zh) 2014-10-22
AU2012288626A8 (en) 2013-09-26
TWI583386B (zh) 2017-05-21
ES2564671T3 (es) 2016-03-28
US20130053409A1 (en) 2013-02-28
EA201792394A2 (ru) 2018-03-30
KR20140030089A (ko) 2014-03-11
KR101422619B1 (ko) 2014-07-24
EP3333161A1 (en) 2018-06-13
MX2014000528A (es) 2014-05-01
AU2012288626B2 (en) 2015-05-07
MY161925A (en) 2017-05-15
IL242286A0 (en) 2015-11-30
EP4086246A1 (en) 2022-11-09
CN105254616A (zh) 2016-01-20
CA2881987C (en) 2017-04-25
PT3009431T (pt) 2017-12-26
SI3686194T1 (sl) 2022-01-31
ES2900230T3 (es) 2022-03-16
EA201391491A1 (ru) 2014-08-29
CA2881991A1 (en) 2013-01-31
IL242285A0 (en) 2015-11-30
EP3333161B1 (en) 2020-02-19
EP4119551A1 (en) 2023-01-18
JP2013544273A (ja) 2013-12-12
LT3009431T (lt) 2018-01-10
US20190092746A1 (en) 2019-03-28
TW201443040A (zh) 2014-11-16
ES2654177T3 (es) 2018-02-12
RS54653B1 (sr) 2016-08-31
PT3686193T (pt) 2022-05-20
CN103702990B (zh) 2015-09-09
SI3009431T1 (en) 2018-01-31
US20240425476A1 (en) 2024-12-26
EP3686193B1 (en) 2022-03-02
PL3686193T3 (pl) 2022-06-13
DK3009431T3 (en) 2018-01-08
US20210130318A1 (en) 2021-05-06
EA029488B1 (ru) 2018-04-30
HK1192554A1 (zh) 2014-08-22
CN104109161B (zh) 2016-08-17
WO2013014448A1 (en) 2013-01-31
SG10201402860QA (en) 2014-08-28
CA2881991C (en) 2016-10-25
BR122014026094B1 (pt) 2020-10-13
EP3686194B1 (en) 2021-09-15
US20240182441A1 (en) 2024-06-06
CN103702990A (zh) 2014-04-02
EP3009431B1 (en) 2017-10-25
US9732058B2 (en) 2017-08-15
HUE056365T2 (hu) 2022-02-28
DK3686193T3 (da) 2022-05-30
PL2736895T3 (pl) 2016-05-31
RS56679B1 (sr) 2018-03-30
JP5537704B2 (ja) 2014-07-02
TWI555743B (zh) 2016-11-01
SG10201402857QA (en) 2014-08-28
UY34219A (es) 2013-02-28
PL3333161T3 (pl) 2020-08-24
HRP20171957T1 (hr) 2018-02-09
US8946235B2 (en) 2015-02-03
EP2736895B1 (en) 2016-01-06
BR112014001768A2 (pt) 2017-02-14
HK1256370A1 (zh) 2019-09-20
CN105254616B (zh) 2017-10-17
CY1120072T1 (el) 2018-12-12
US20190389834A1 (en) 2019-12-26
HUE026429T2 (en) 2016-05-30
PE20141700A1 (es) 2014-11-20
CN105348266A (zh) 2016-02-24
CN105348266B (zh) 2018-04-10
HRP20160135T1 (hr) 2016-03-11
US10017493B2 (en) 2018-07-10
JP5977779B2 (ja) 2016-08-24
EA033733B1 (ru) 2019-11-20
SMT201600070B (it) 2016-04-29
PL3686194T3 (pl) 2022-01-17
IL242279A0 (en) 2015-11-30
JP5427321B2 (ja) 2014-02-26
CO6811863A2 (es) 2013-12-16
KR101410902B1 (ko) 2014-06-20
BR122014026150B1 (pt) 2020-10-13
AU2012288626A1 (en) 2013-05-02
IL242278A (en) 2016-12-29
CY1117431T1 (el) 2017-04-26
HUE037645T2 (hu) 2018-09-28
EA201792394A3 (ru) 2018-07-31
CN105175396A (zh) 2015-12-23
CA2881993A1 (en) 2013-01-31
CA2882018C (en) 2017-04-25
BR122014026114B1 (pt) 2021-01-12
DK3686194T3 (da) 2021-11-22
EA201690328A1 (ru) 2016-11-30
MX377900B (es) 2025-03-10
BR122014026114A2 (pt) 2019-08-20
CA2882018A1 (en) 2013-01-31
LT3333161T (lt) 2020-05-11
ME02887B (me) 2018-04-20
US20150119379A1 (en) 2015-04-30
EP3009431A1 (en) 2016-04-20
HRP20211682T1 (hr) 2022-03-04
EP3686193A1 (en) 2020-07-29
HRP20200624T1 (hr) 2020-07-10
MY194532A (en) 2022-11-30
GT201300288A (es) 2017-10-09
SI3333161T1 (sl) 2020-07-31
KR20140047741A (ko) 2014-04-22
CN104109161A (zh) 2014-10-22
JP2014094930A (ja) 2014-05-22
US20180162832A1 (en) 2018-06-14
EA024421B1 (ru) 2016-09-30
US11524951B2 (en) 2022-12-13
CN105198862A (zh) 2015-12-30
CA2843109C (en) 2015-06-16
CN104109151B (zh) 2017-04-12
CY1123210T1 (el) 2021-10-29
PT3333161T (pt) 2020-05-18
SMT202100652T1 (it) 2022-01-10
TW201700099A (zh) 2017-01-01
PH12015501326A1 (en) 2015-09-14
AU2012288626C1 (en) 2015-09-17
CA2881993C (en) 2017-05-09
NI201300134A (es) 2014-02-12
SMT202000208T1 (it) 2020-05-08
BR112014001768B1 (pt) 2019-02-05
MX2020013020A (es) 2022-06-14
SI2736895T1 (sl) 2016-03-31
DK2736895T3 (da) 2016-02-29
RS62542B1 (sr) 2021-12-31
TWI465445B (zh) 2014-12-21
CL2013003281A1 (es) 2014-07-25
KR20140062181A (ko) 2014-05-22
PL3009431T3 (pl) 2018-02-28
CA2881987A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
US20240182441A1 (en) 2-(2,4,5-substituted-anilino)pyrimidine compounds
HK40082765A (zh) 作为egfr调谐子的2-(2,4,5-取代苯胺)嘧啶化合物
HK40086830A (zh) 2-(2,4,5-取代苯氨基)嘧啶衍生物
AU2015261672B2 (en) 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
HK1256370B (zh) 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调节子用於治疗癌症
AU2013204962B2 (en) Polymorphic form of a mesylate salt of n-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
HK1221216B (zh) 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用於治疗癌症
HK1192549B (zh) 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用於治疗癌症
NZ617393B2 (en) 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer